Company Overview
Snapshot
Founded in January 2017 by Yaakov Nahmias, Tissue Dynamics operates with 11–50 employees. The company has raised $3.26M across two funding rounds. In February 2024, Tissue Dynamics announced a strategic collaboration with ATCC to bring a transformative heart organoid model to market.
Business overview
Tissue Dynamics is a biotechnology company focused on transforming drug and cosmetic development through advanced organ-on-chip (OOC) tools. The company's bionic OOC platform provides 3D microphysiological models that emulate human physiology with real-time monitoring and smart algorithm analysis. This technology aims to increase clinical success rates and reduce R&D costs in the pharmaceutical, nutraceutical, and cosmetic industries by offering human-relevant models and sensor-driven discovery.
Strategic signal
In May 2026, Tissue Dynamics announced a collaboration with Galmed Pharmaceuticals to develop a human-centered chronic cardiac fibrosis platform. This partnership is significant as it aims to advance Aramchol-based therapeutics, indicating a strategic move to apply Tissue Dynamics' OOC technology to specific disease models and validate its platform's utility in drug development for chronic conditions.
Log in to access full profile ›Company Intelligence Q&A
- What is Tissue Dynamics' core focus?
- Tissue Dynamics is committed to transforming drug and cosmetic development by advancing next-generation organ-on-chip (OOC) tools for the pharmaceutical, nutraceutical, and cosmetic industries.
- When was Tissue Dynamics founded?
- Tissue Dynamics was founded in January 2017.
- What significant collaboration did Tissue Dynamics announce in February 2024?
- In February 2024, Tissue Dynamics announced a strategic collaboration with ATCC to bring a transformative heart organoid model to market.
- What is the total capital raised by Tissue Dynamics?
- Tissue Dynamics has raised a total of $3.26M across two funding rounds.
- What recent partnership did Tissue Dynamics form to advance cardiac fibrosis therapeutics?
- In May 2026, Tissue Dynamics partnered with Galmed Pharmaceuticals to develop a human-centered chronic cardiac fibrosis platform to advance Aramchol-based therapeutics.